newsfilter
← Latest News
GlobeNewswire·

iTeos Reports Third Quarter 2023 Financial Results and Provides Business Updates

- Initiation of GALAXIES H&N-202, a Phase 2 platform study assessing TIGIT:PD-1 doublet and other novel IO combinations, including a CD96 triplet in HNSCC - Completed enrollment of monotherapy dose escalation arm in